

Extraction and Prevalence of Structured Data Elements in Free-Text Clinical Trial Eligibility Criteria

Christian Gulden, Inge Landerer, Azadeh Nassirian, Fatma Betül Altun,
Johanna Andrae

EFMI STC 2019



Background & Motivation

- Recruitment into clinical trials remains challenging:
 - McDonald et al, 2006 [1]:
“**Less than a third (31%)** of the trials achieved their original recruitment target”
 - Sully et al, 2008 [2]:
“[...] **(55%)** of trials recruited their originally specified target sample size, with over three-quarters (78%) recruiting 80% of their target. [...] **Nearly half (45%)** of trials received an extension of some kind.”


[1] McDonald AM, Knight RC, Campbell MK, et al. *What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies*. *Trials*. 2006;7:9. Published 2006 Apr 7. doi:10.1186/1745-6215-7-9

[2] Sully BG, Julious SA, Nicholl J. *A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies*. *Trials*. 2013;14:166. Published 2013 Jun 9. doi:10.1186/1745-6215-14-166

- (Manual) Recruitment fails to achieve its goals
- How about semi-automatic recruitment using computers?
- Electronic Health Records (EHRs) contain large quantities of patient data viable for recruitment
- Use this data to automatically recommend patients for clinical trials to practitioners

MII MIRACUM Use Case: IT-Support for patient recruitment

- Leverage Digitilization in Medicine for Research and Care in Germany
- 4 consortia (MIRACUM, HIGHmed, SMITH, DIFUTURE)
- Build Data Integration Centers (DICs) containing harmonized data from various source systems
- Implement IT-Solutions (Use Cases) based on these DICs




miracum

Medical Informatics in Research and Care in University Medicine

Use Case: IT Support for Patient Recruitment

- Simplified



What structured data elements are the most relevant for clinical trial eligibility screening?

Methods


1. Select 50 clinical trials
2. Extract the free-text eligibility criteria
3. Distribute the criteria among the 10 MIRACUM sites
4. Analyze the criteria and extract structured data elements
5. Validate and harmonize the extracted data elements
6. Generate summary statistics over the results

- Source: clinicaltrials.gov
- Actively recruiting
- At least one MIRACUM site is participating in the trial
- Represent a broad range of clinical disciplines
 - Oncology, neurology, ...

Extraction of Criteria



```
1 <clinical_study>
2   <required_header>
3     <download_date>
4     ClinicalTrials.gov processed this data on March 11, 2019
5     </download_date>
6     <link_text>Link to the current ClinicalTrials.gov record.</link_text>
7     <url>https://clinicaltrials.gov/show/NCT03870100</url>
8   </required_header>
9   <id_info>
10    <org_study_id>SHR-1222-101</org_study_id>
11    <nct_id>NCT03870100</nct_id>
12  </id_info>
13  <brief_title>
14  The Safety, Tolerability and PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in H
15  </brief_title>
16  <official_title>
17  Use the Protocol Title. The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study
18  </official_title>
19  <sponsors>
20    <lead_sponsor>
21      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
22      <agency_class>Industry</agency_class>
23    </lead_sponsor>
24  </sponsors>
25  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
26  <oversight_info>
27    <has_dmc>No</has_dmc>
28    <is_fda_regulated_drug>No</is_fda_regulated_drug>
29    <is_fda_regulated_device>No</is_fda_regulated_device>
30  </oversight_info>
31  <brief_summary>
32    <textblock>
33  This is a Single Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Control
34    </textblock>
35  </brief_summary>
36  <detailed_description>
37    <textblock>
38  50 adult healthy subjects with 5 dose groups will be enrolled in the study, including six sub
39    </textblock>
40  </detailed_description>
41  <overall_status>Not yet recruiting</overall_status>
42  <start_date type="Anticipated">March 20, 2019</start_date>
43  <completion_date type="Anticipated">November 30, 2019</completion_date>
44  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
45  <phase>Phase 1</phase>
```



Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (ESOPEC)

<https://clinicaltrials.gov/ct2/show/NCT02509286>

Inclusion-Criteria

Free-text Criteria

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)

Sexes Eligible for Study: All

Histologically verified adenocarcinoma of the esophagus according to the UICC definition (TNM7)

Pre-treatment stage cT1N+, M0 or cT2-4a, N0/+, M0

Age ≥ 18 years

No prior abdominal or thoracic radiotherapy


ECOG Performance status 0-2

Adequate cardiac function (Patients with a cardiac history (e.g. myocardial infarction, heart failure, coronary artery

XML

HTML

Distribute Work



 **Confluence**

50 Trials

5 Trials / site

Extraction of Structured Data Elements


| Criteria | Simplified | Objective | Group | Element |
|---|------------|-----------|-------|---------|
| Age \geq 18 years | | | | |
| ECOG Performance status 0-2 | | | | |
| Subject has a clinically relevant ECG abnormality, in the opinion of the investigator | | | | |
| Hepatorenal syndrome (type I or II) or screening serum creatinine >2 mg/dL (178 μ mol/L) | | | | |
| | | | | |
| ... | | | | |

Extraction of Structured Data Elements

| Criteria | Simplified | Objective | Group [1] | Element [1] |
|---|--|-----------|--------------------------|-------------------------|
| Age ≥ 18 years | | ✓ | Demographics | Date of Birth |
| ECOG Performance status 0-2 | | ✓ | Scores & Classifications | ECOG Performance Status |
| Subject has a clinically relevant ECG abnormality, in the opinion of the investigator | | ✗ | | |
| Hepatorenal syndrome (type I or II) or screening serum creatinine >2 mg/dL (178 µmol/L) | Hepatorenal syndrome (type I or II) | ✓ | Diagnosis | Diagnosis code |
| | Screening serum creatinine >2 mg/dL (178 µmol/L) | ✓ | Laboratory Findings | Creatinine in serum |
| ... | | | | |


[1] Doods, Justin et al. "A European inventory of data elements for patient recruitment." Studies in health technology and informatics 210 (2015): 506-10 .

Harmonize Results




Results

- Total number of trials registered on clinicaltrials.gov: 277.228
- Currently recruiting and MIRACUM site is participating: 416
- Manual filtering yielded final 50, e.g.
 - Removing post-market and registry studies
 - achieving broad representation of disciplines



- Total of **1.120** free-text criteria (inclusion + exclusion)
- Mean number of criteria per study: **22** (IQR=18, Range=6-49)
- **130** (12 %) were identified as non-objective
- Total of **1.625** data elements extracted
- **204** unique items remained
(after harmonization and aggregating duplicates)

Distribution



Discussion & Outlook

- Prioritized list of data elements required to be present in the EHR to facilitate semi-automated patient recruitment
- Manual approach is quality-assured, but exceptionally labor-intensive

- Automated methods to extract data elements:
 - See work by Weng et al. [1]
 - Automatically assess how well a study may be supported by semi-automated patient recruitment systems.
 - Automatically formalize criteria. See Criteria2Query [2], EliIE [3]
- Future work:
 - Analyzing the data quality of EHRs for the purpose of patient recruitment based on the data in this work

[1] Butler A, Wei W, Yuan C, Kang T, Si Y, Weng C. The Data Gap in the EHR for Clinical Research Eligibility Screening. *AMIA Jt Summits Transl Sci Proc.* 2018;2017:320–329. Published 2018 May 18.

[2] Yuan C, Ryan PB, Ta C, et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. *J Am Med Inform Assoc.* 2019;26(4):294–305. doi:10.1093/jamia/ocy178

[3] Kang T, Zhang S, Tang Y, et al. EliIE: An open-source information extraction system for clinical trial eligibility criteria. *J Am Med Inform Assoc.* 2017;24(6):1062–1071. doi:10.1093/jamia/ocx019

Cheers to the MIRACUM UC1 Team!

Erlangen

Christian Gulden, Hans-Ulrich Prokosch

Dresden

Martin Sedlmayr, Christian Kamann, Azadeh Nassirian

Frankfurt

Kristina Götze, Betül Altun

Freiburg

Martin Boeker, Johanna Andrae, Saskia Kiefer, Adrian Tassoni, Inge Landerer

Gießen

Romina Blasini, Florian Eberhardt, Achim Michel-Backofen

Greifswald

Thomas Bahls, Torsten Leddig, Kai Fitzer, Martin Bialke

Mainz

Tony Hauptmann, Marcel Stark, Gunther Höning

Mannheim

Oliver Opitz, Thomas Ganslandt,

Marburg

Jens-Peter Reese, Michael Wittenberg, Thomas Wündisch, Martin Middeke

Magdeburg

Johannes Bernarding, Tim Herrmann, Anke Lux, Philipp Bornfleth

Thank you for your attention!